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LETTERS TO 
THE EDITOR
Effect o f iV-acetyl cysteine 
on thiol levels
We read with interest the article by Dr Bridge- 
man and colleagues on the effect of oral 
N-acetyl cysteine (NAC) on thiol levels in 
epithelial lining fluid (ELF) and lung tissue 
(July 1994;49:670-5). Their suggestion that 
NAC may not be the drug of choice to en­
hance the glutathione antioxidant potential 
of the lungs in chronic obstructive pulmonary 
disease (COPD) is not supported by their 
data, since levels of cysteine or glutathione 
in ELF, bronchoalveolar lavage (BAL) fluid, 
or lung tissue were not measured in these 
patients. In addition, they did not perform 
functional measurements.
Several studies have investigated the anti- 
oxidative capacity of NAC, 600 mg daily. In 
healthy smokers significant decreases in levels 
of lactoferrin, ECP> and chemoractic activity 
of neutrophils in BAL fluid, and of myelo­
peroxidase and elastase levels in serum, were 
found.12 Treatment with NAC, 200 mg twice 
or three times daily for more than one year, 
was associated with a decrease in the number 
of bacteria, especially in patients with 
COPD.3 The design of some of these studies 
precludes firm conclusions, but they at least 
suggest that conventional doses of NAC may 
influence the antioxidative capacity of the 
lung. This is of special relevance in those 
patients with a significantly disturbed pul­
monary oxidative/anti oxidative balance, such 
as patients with COPD and smokers. Indeed, 
Lundback et al recently showed that two years 
of treatment with NAC, 600 mg daily, re­
duced the annual decline in FEV! compared 
with a control group.4 This effect was most 
pronounced in smoking patients over 50 years 
of age with already considerably decreased
FEV,.
Looking at the pharmacokinetic data, the 
authors showed in a group of patients con­
sisting of smokers, ex-smokers and non- 
smokers that NAC, 600 mg daily for five days, 
increased levels of glutathione in BAL fluid 
by 180% 1-3 hours after the last dose 
(p<0*05), and by 24% 16-20 hours after the 
last dose (NS).5 This “transient” increase in 
antioxidants in the lung apparently does not 
preclude a decrease in oxidative stress, or an 
improvement in antioxidative capacity of the 
lung, or both.
PNR DEKHUIJZEN 
CLA VAN HERWAARDEN
Department of Pulmonology 
Academic Hospital Nijmegen,
PO Box 9101 
6500 HB Nijmegen, 
The Netherlands
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a u t h o r s ’ r e p l y  We thank Drs Dekhuijzen 
and van Herwaarden for their interest in our 
paper. We do not, however, agree with their 
conclusions. Although the patients in whom  
measurements o f glutathione and cysteine in 
BAL fluid and lung tissue were performed 
were not specifically chosen as having COPD, 
these patients were all smokers or ex-smokers, 
as stated in the text, and table 1 clearly in­
dicates that some had airflow limitation as 
shown by the predicted values for FEV!. 
Thus, some of these patients had COPD. 
The results of measurements o f thiol con­
centrations in plasma in our study also suggest 
that, even with high doses of 2V-acetyl cyst­
eine, the plasma concentrations of thiols in 
patients with COPD were lower than in nor­
mal subjects. The lack of any significant 
changes in thiol concentrations in BAL fluid 
and lung tissue in this group o f  patients with 
minor airflow limitation suggests that levels 
in lung and BAL fluid would be even lower 
in patients with severe COPD.
The purpose of our study was not to assess 
any “functional” measurements but simply, 
as stated in the title, to determine whether 
there was a significant increase in thiol con­
centrations in plasma, BAL fluid, and lung 
tissue following administration of JV-acetyl 
cysteine. We are aware of studies which sug­
gest a decrease in exacerbation of symptoms 
in patients with COPD treated with N-acetyl 
cysteine. We are also aware, and state in the 
paper, that the beneficial effect on ex­
acerbations of COPD has been shown in 
some, but not all, studies. The purpose of our 
study was to determine whether the possible 
beneficial effects o f iV-acetyl cysteine could 
be explained by a significant change in thiol 
concentrations -  and hence the antioxidant 
potential -  in BAL fluid and in the lungs.
Drs Dekhuijzen and van Herwaarden are 
clearly aware o f our previous data. However, 
we were unable to confirm a sustained sig­
nificant increase in glutathione levels in die 
lung or BAL fluid with high doses of AT-acetyl 
cysteine. These studies therefore lead us to 
conclude that iV-acetyl cysteine, even in high 
doses, failed to produce any sustained or 
significant increase in thiol concentrations in 
the lung. We must therefore seek an al­
ternative explanation for the beneficial effects 
of AT-acetyl cysteine shown in some studies 
in patients with COPD.
W  M ACNEE 
Respiratory Medicine Unit, 
Department of Medicine (RIB),
Royal Infirmary, 
Edinburgh EH3 9YW>
UK
Asthma publications
The incidence of asthma is high in most 
communities and possibly increasing,1 and 
is associated with considerable morbidity.2 
Physicians have been aware of the links with 
allergy throughout most of this century and, in 
broad outline, the concept of the interaction 
between IgE and antigens in the bronchi is 
similar to that held in the 1970s. The fact 
that histological changes similar in quality to 
those found at post mortem examination are 
present even in mild asthma suggests that an 
immunological process is frequently going on 
in atopic subjects.3 It is well recognised that 
apparent respiratory infections and exposures 
to some antigens, in particular the house dust 
mite34 is associated with an increase in the 
incidence of asthma.
Since for all diseases it is logical to consider 
that prevention is better than cure, one would 
expect that the major push in research in 
asthma would be towards finding methods to 
reduce antigen exposure. In 1993 Thorax3 
the journal of the British Thoracic Society, 
published 280 papers, 30-7% of which were 
on the subject of asthma. In the same year 
the American Review of Respiratory Diseases, 
the journal of the American Thoracic Society, 
published 540 papers of which 31*8% were 
on the same subject. The distribution o f the 
type of asthma research published in the two 
journals is shown in the table, although nat­
urally diere are some areas of overlap. It can 
be seen that neither journal has published 
many papers on the household or external 
environment. The American Review of Re­
spiratory Diseases has concentrated on allergy 
and general aspects of the disease, while 
Thorax has concentrated on the treatment.
It is natural that biological researchers 
should be interested in the details of pa­
thophysiology and the exciting spectrum o f  
lytnphokines, adhesion molecules and me­
diators for their own sake, as well as the hope 
that in the future a cure for asthma might be 
found. Asthma patients and their physicians 
owe a great debt of gratitude to the phar­
maceutical industry for the drugs they have 
produced, especially since the 1970s. When 
used correctly these have been of benefit to 
most patients and have been a rich resource 
for research as is obvious from the pub- 
lications* especially in the British journal. I 
wonder, however, if, as physicians and not 
as researchers, we should be asking if the 
direction of asthma investigation has drifted 
too much away from the prevention of ob­
vious excessive exposure to antigens.
CF STANFORD 
Depanmem of Medicine,
KKNGH, 
PO Box 9516, 
Jeddah 21423, 
Saudi Arabia
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Pulmonary 
M y co bac terium  
■malmoense and 
Aspergillus infection
I read with great interest the paper by Dr 
FGE Bollert et al (May 1994;49:521-2). I 
recently described a case of pulmonary Myco- 
bacterium malmoense with superadded Asper­
gillus infection1 and would like to make several 
additional comments.
I pointed out that coexisting infection was 
a problem and was associated with a poorer 
prognosis, Our patient died a few weeks after 
the initial evidence of fungal infection. Evid­
ence of active pulmonary mycobacteriosis was 
assessed on post mortem examination after 
20 months of antituberculous chemotherapy 
and thoracic surgery with residual signs o f  
abscess cavities and pulmonary destruction. 
Aspergillus is likely to colonise these cavities 
and cause an aspergilloma as described in 
cases o f tuberculosis.
Long term chemotherapy failed to sterilise 
the sputum and there was no evidence of 
clinical or radiological improvement of the 
mycobacterial infection. Surgery was per­
formed, firstly, for mycobacteriosis as other 
authors have described23 and, secondly, be­
cause of the aspergilloma. There was no evid­
ence o f fungal invasion but fungal hyphae 
were present in the cavity.
Aggressive treatment is indicated for the 
two infections: antituberculous (with etham- 
butol) and antifungal therapy (itraconazole) 
plus surgery if possible. Aspergillus is a sig­
nificant opportunistic agent in M  malmoense 
pulmonary infection.
D DEBIEUVRE
Service de Pneumologie et Allergologte, 
Centre Hospiialier General Paid-Morel,
BP 409 
70014 Vesoul, 
France
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Empyema and 
m ediastinitis with 
retropharyngeal abscess
I have read with interest the report by Dr 
M Watanabe and his colleagues (November 
1994;49:1179-80) reporting empyema and 
mediastinitis complicating a retropharyngeal 
abscess. Only a few months ago a 61 year old 
woman was referred to me with a short history 
of severe pharyngitis on an initially normal 
pharyngoscopy. She rapidly became ex­
tremely ill with evidence of mediastinitis, 
surgical emphysema, and a right sided 
empyema. The causative organisms in our 
patient were Gamella haemolysans and Strepto­
coccus milleri and we treated the patient with 
urgent right thoracotomy and drainage of the 
empyema and mediastinum. At the time of 
thoracotomy inspection of the pharynx re­
vealed a ruptured abscess in the left pyriform 
fossa.
We can confirm Dr Watanabe’s conclusion 
that this is a rare condition but, with early 
drainage of the abscess, a favourable outcome 
should be expected. Our patient has made an 
uneventful recovery and has been discharged 
from follow up after review at two months.
D C T  WATSON
Regional Department of Thoracic Surgejy, 
Bimnngham Heartlands Hospital
Bordesley Green East, 
Bmningliam B9 5SS,
UK
BOOK NOTICES
E ndotoxin  and the Lungs. Kenneth L 
Brigham. (Pp 536; $175 .00). N ew  York: Mar­
cel Dekker, 1994, 0 8247 9222 X.
This represents Volume 77 of die first rate 
clinical and scientific series published by Mar­
cel Dekker entided “Lung Biology in Health 
and Disease”. These fine (principally) sci­
entific monographs are on subjects of interest 
to thoracic physicians. In fact, the current 
volume represents nicely the historical and 
established overlap between pulmonary and 
critical care medicine in North America. 
There is an enormous literature on endotoxin, 
but the editor hopes that this volume will cast 
new light on the core of information about 
endotoxin relevant to clinical medicine by 
placing the scientific data in a clinical context. 
This review, I feel, has achieved this aim 
admirably. Chapters dealing with the chem­
ical structure and biological activity of endo­
toxin are interspersed with those dealing with 
receptive and second messenger pathways. 
There is a first rate chapter on LPS-induced 
signal transduction in gene transcription and 
the chapter dealing with the effects of the 
anatomical and functional effects of endo­
toxin on the endothelium is very good. As 
lung injury and acute respiratory distress in 
adults (ARDS) are increasingly regarded by 
many authorities as only the pulmonary mani­
festation of a panendothelial insult, I would 
have liked to see more space devoted to the 
effects of endotoxin on systemic and peri­
pheral and microvascular control mech­
anisms, although these are touched upon in 
a chapter dealing with sepsis. The chapter 
dealing with immunological therapy in endo- 
toxaemia is disappointing -  not in its content, 
but rather because of the failure of such ap­
proaches to produce any significant fall in the 
high mortality associated with these clinical 
conditions. Nevertheless, the volume ends on 
an up-beat note: the chaper on the prospects 
of gene therapy in this area is not only exciting 
but contains sufficient preliminary data to 
give us a glimmer of hope that real therapeutic 
advances may be in sight at last. -  TWE
Neuropeptides in Respiratory Medicine.
MA Kaliner, PJ Barnes, GHH Kunkel, JN 
Baraniuk. (Pp 728; $195.00). New York: 
Marcel Dekker, 1994. 0 8247 9199 1.
Rather dian being a textbook, this is a record 
of conference proceedings. The chapters are 
a mixture of topical overview which vary in 
tiieir degree of incisive comment and pre­
sentation of experimental data with attendant 
risks of subjectivity. Typographical errors are 
rare although grammatical structure, par­
ticularly of the transcribed “discussion” sec­
tions which follow most chapters, makes 
reading difficult.
Despite the general title, this book is se­
lective in its coverage of this interesting topic. 
The introduction promises a more systematic 
approach than the book delivers, where some 
of the basic science is not discussed further in 
terms of physiological or pathophysiological 
mechanisms. The major topic of the book, 
however, concerns neuropeptide modulation 
of airway function which is dealt with com­
prehensively from general molecular biology 
through to potential therapeutic targets. 
Some other concepts and diseases discussed 
would have benefited from a similar meth­
odical approach.
Other than in relation to asthma, w e are 
given little insight into the clinical relevance of 
the neuropeptides. Their role in the selected 
diseases mentioned is discussed mainly in the 
context of mechanistic theories rather than 
potential therapeutic strategies. One obvious 
omission is any discussion on the role of 
neuropeptides in the pulmonary circulation 
or in relation to pulmonary vascular disease 
where a large body of work does exist.
The book does, however, contain a wealth 
of up-to-date reference material. As such, it 
is likely to be of most value to workers already 
engaged in related fields of research where 
the investment of S I95 might be wordiwhile. 
For the wider population of researchers and 
clinicians in respiratory medicine the book, 
like its subject matter, is mostly of uncertain 
relevance to current clinical practice. -  RIC
